Declining prevalence of HIV-1 drug resistance in treatment-failing patients: A clinical cohort study

Antiviral Therapy

Volumn 12, Issue 5, 2007, Pages 835-839

  Di Giambenedetto, Simona ^a   Bracciale, Laura ^a   Colatigli, Manuela ^a   Pannetti, Carmen ^a   Bacarelli, Alessandra ^a   Prosperi, Mattia ^b   Fadda, Giovanni ^a   Cauda, Roberto ^a   De Luca, Andrea ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b ROMA TRE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PREVALENCE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; POPULATION SURVEILLANCE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; SEX FACTORS; TIME FACTORS; TREATMENT FAILURE;

EID: 34547729075     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-48.
2. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-128.
3. Gottlieb GS, Hawes SE, Agne HD, et al. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 2006; 20:895-900.
4. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2006; 192:958-966.
5. Johnson VA, Brun-Vézinet F, Closet B, et al. Update of the Drug Resistance Mutations in HIV-1: Fall 2005. Top HIV Med 2005; 13:125-131.
6. Tamalet C, Fantini J, Toures C, Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 2003; 17:2383-2388.
7. Scott P, Arnold E, Evans B, et al. Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother 2004; 53:469-473.
8. Richman DD, Morton SC, Wrin TF, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-1401.
9. Pillay D, Green H, Matthias R, et al. UK Collaborative Group on HIV Drug Resistance. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis 2005; 192:967-973.
10. Health Protection Agency. CDR Weekly 2006; 16:14-18.
11. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60.
12. MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 2004; 18:651-655.
13. Lohse N, Obel N, Kronborg G, et al. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther 2006; 11:591-600.
14. Temesgen Z, Cainelli F, Poeschla EM, et al. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect Dis 2006; 6:496-507.
15. Ledergerber B, Walker AS, Sabin C, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-62.
16. Murri R, Lepri AC, Cicconi P, et al. Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study. J Acquir Immune Defic Syndr 2006; 41:23-30.